Lilly Touts Foundayo Over Novo Pill
Eli Lilly reported that its oral drug Foundayo achieved greater weight loss and better blood sugar control than Novo Nordisk's Ozempic pill in type 2 diabetes patients. The findings stem from an indirect data comparison between the two rival treatments.
Insights:
Eli Lilly reported Tuesday morning that its oral obesity drug Foundayo delivered greater weight loss and better blood sugar control than a higher dose of Novo Nordisk's oral pill in adults with type 2 diabetes. The analysis relied on an indirect comparison using data from two previous late-stage clinical trials. Both pharmaceutical giants are battling for market share in the rapidly expanding GLP-1 treatment landscape.
